Literature DB >> 24964699

Handling time in economic evaluation studies.

Unchalee Permsuwan, Kansinee Guntawongwan, Piyaluk Buddhawongsa.   

Abstract

The discount rates and time horizons used in a health technology assessment (HTA) can have a significant impact on the results, and thus the prioritization of technologies. Therefore, it is important that clear guidance be provided on the appropriate discount rates for cost and health effect and appropriate time horizons. In this paper we conduct a review of relevant case studies and guidelines and provide guidance for all researchers conducting economic evaluations of health technologies in the Thai context. A uniform discount rate of 3% is recommended for both costs and health effects in base case analyses. A sensitivity analysis should also be conducted, with a discount range of 0-6%. For technologies where the effects are likely to sustain for at least 30y ears, a rate of 4% for costs and 2% for health effects is recommended. The time horizon should be long enough to capture the full costs and effects of the programs.

Mesh:

Year:  2014        PMID: 24964699

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  17 in total

1.  Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.

Authors:  Khachen Kongpakwattana; Zanfina Ademi; Thanaputt Chaiyasothi; Surakit Nathisuwan; Ella Zomer; Danny Liew; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2019-10       Impact factor: 4.981

2.  Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.

Authors:  Rungroj Krittayaphong; Unchalee Permsuwan
Journal:  Am J Cardiovasc Drugs       Date:  2022-07-07       Impact factor: 3.283

3.  Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.

Authors:  Piyameth Dilokthornsakul; Ratree Sawangjit; Pisit Tangkijvanich; Maneerat Chayanupatkul; Tawesak Tanwandee; Wattana Sukeepaisarnjaroen; Pajaree Sriuttha; Unchalee Permsuwan
Journal:  Appl Health Econ Health Policy       Date:  2022-02-10       Impact factor: 3.686

4.  Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand.

Authors:  Unchalee Permsuwan; Arintaya Phrommintikul; Voratima Silavanich
Journal:  Clinicoecon Outcomes Res       Date:  2020-10-14

5.  Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand.

Authors:  Chaicharn Deerochanawong; Kriengsak Vareesangthip; Dilok Piyayotai; Dittaya Thongsuk; Nuch Pojchaijongdee; Unchalee Permsuwan
Journal:  Diabetes Ther       Date:  2021-06-09       Impact factor: 2.945

6.  Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand.

Authors:  Unchalee Permsuwan; Piyameth Dilokthornsakul; Surasak Saokaew; Kednapa Thavorn; Nathorn Chaiyakunapruk
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-21

7.  Comparative Effectiveness of Local Application of Chlorhexidine Gluconate, Mupirocin Ointment, and Normal Saline for the Prevention of Peritoneal Dialysis-related Infections (COSMO-PD Trial): a multicenter randomized, double-blind, controlled protocol.

Authors:  Surapon Nochaiwong; Chidchanok Ruengorn; Kajohnsak Noppakun; Setthapon Panyathong; Phongsak Dandecha; Manish M Sood; Chalermpong Saenjum; Ratanaporn Awiphan; Sasithorn Sirilun; Pajaree Mongkhon; Wilaiwan Chongruksut; Kednapa Thavorn
Journal:  Trials       Date:  2019-12-19       Impact factor: 2.279

8.  The cost utility and budget impact of adjuvant racecadotril for acute diarrhea in children in Thailand.

Authors:  Tamlyn Anne Rautenberg; Ute Zerwes
Journal:  Clinicoecon Outcomes Res       Date:  2017-07-17

9.  Endovenous ablation and surgery in great saphenous vein reflux: a systematic review and network meta-analysis of randomised controlled trials protocol.

Authors:  Boonying Siribumrungwong; Kanoklada Srikuea; Saritphat Orrapin; Thoetphum Benyakorn; Kittipan Rerkasem; Ammarin Thakkinstian
Journal:  BMJ Open       Date:  2019-01-30       Impact factor: 2.692

10.  Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction.

Authors:  Rungroj Krittayaphong; Jirawit Yadee; Unchalee Permsuwan
Journal:  Clinicoecon Outcomes Res       Date:  2019-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.